Literature DB >> 14613283

The -174G allele of the interleukin-6 gene confers susceptibility to systemic arthritis in children: a multicenter study using simplex and multiplex juvenile idiopathic arthritis families.

Emma M Ogilvie1, Mark S Fife, Susan D Thompson, Natalie Twine, Monica Tsoras, Marta Moroldo, Sheila A Fisher, Cathryn M Lewis, Anne-Marie Prieur, David N Glass, Patricia Woo.   

Abstract

OBJECTIVE: Levels of interleukin-6 (IL-6) have been shown to correlate with the fever and disease activity of systemic juvenile idiopathic arthritis (JIA). In a previous case-control study, a significant association between the IL-6 -174 nucleotide variant and systemic JIA was noted, and HeLa cell transfection assays show functional differences in levels of transcription of the IL-6 -174 alleles. The present study was undertaken to confirm the previous findings and to assess possible association with variations of the A(n)T(n) tract in the promoter.
METHODS: We studied a cohort of JIA families from 3 countries, using transmission disequilibrium testing. Genotyping of the -174 nucleotide variant was done by restriction fragment length polymorphism, heteroduplex analysis, or allelic discrimination. The A(n)T(n) tract at -392 to -373 was typed using DNA sequencing. Statistical analysis was performed using the programs Transmit and EHplus.
RESULTS: There was a significant excess transmission of the -174G allele in the systemic JIA families (P = 0.041). The excess transmission was only to systemic JIA patients with age at onset >5 years (P = 0.007). No significant association with the other subtypes was found. No A(n)T(n) alleles or -174/A(n)T(n) haplotypes were significantly associated with systemic JIA.
CONCLUSION: This study confirms that the IL-6 -174 nucleotide variant is significantly associated with systemic JIA. The significant excess transmission to patients with age at onset >5 years but not to those with age at onset < or =5 years suggests that there may be genetic heterogeneity between the 2 groups.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14613283     DOI: 10.1002/art.11300

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  41 in total

Review 1.  Inhibition of IL-1, IL-6, and TNF-alpha in immune-mediated inflammatory diseases.

Authors:  Burkhard Möller; Peter M Villiger
Journal:  Springer Semin Immunopathol       Date:  2006-05-09

Review 2.  [Still's disease in children and adults].

Authors:  C M Hedrich; C Günther; M Aringer
Journal:  Z Rheumatol       Date:  2017-09       Impact factor: 1.372

3.  Interleukin-6 gene polymorphism in Iranian patients with systemic lupus erythematosus.

Authors:  Esmaeil Moazemi Godarzi; Eskandar Kamali Sarvestani; Elham Aflaki; Zahra Amirghofran
Journal:  Clin Rheumatol       Date:  2010-04-11       Impact factor: 2.980

4.  MEFV mutations in Egyptian children with systemic-onset juvenile idiopathic arthritis.

Authors:  Hala M Lotfy; Manal E Kandil; Marianne Samir Makboul Issac; Samia Salah; Nagwa Abdallah Ismail; Mohamed A Abdel Mawla
Journal:  Mol Diagn Ther       Date:  2014-10       Impact factor: 4.074

Review 5.  Pathogenesis of systemic juvenile idiopathic arthritis: some answers, more questions.

Authors:  Elizabeth D Mellins; Claudia Macaubas; Alexei A Grom
Journal:  Nat Rev Rheumatol       Date:  2011-06-07       Impact factor: 20.543

6.  Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis.

Authors:  Shumpei Yokota; Toshio Tanaka; Tadamitsu Kishimoto
Journal:  Ther Adv Musculoskelet Dis       Date:  2012-12       Impact factor: 5.346

Review 7.  The varying faces of IL-6: From cardiac protection to cardiac failure.

Authors:  Jillian A Fontes; Noel R Rose; Daniela Čiháková
Journal:  Cytokine       Date:  2015-01-31       Impact factor: 3.861

8.  Tocilizumab: The evidence for its place in the treatment of juvenile idiopathic arthritis.

Authors:  Troels Herlin
Journal:  Core Evid       Date:  2010-06-15

Review 9.  [Juvenile idiopathic arthritis--clinical subgroups and classification].

Authors:  K Minden; M Niewerth
Journal:  Z Rheumatol       Date:  2008-03       Impact factor: 1.372

10.  Biological therapies for the treatment of juvenile idiopathic arthritis: Lessons from the adult and pediatric experiences.

Authors:  Matthew L Stoll; Alisa C Gotte
Journal:  Biologics       Date:  2008-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.